Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?

Calin O. Marian, Jerry W. Shay

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.

Original languageEnglish (US)
Pages (from-to)289-296
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1792
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Neoplastic Stem Cells
Telomerase
Prostate
Prostatic Neoplasms
Ribonucleoproteins
Telomere
Therapeutics
Androgens
Neoplasms
Radiotherapy
Recurrence
Drug Therapy
Enzymes
Population

Keywords

  • GRN163L
  • Prostate
  • Telomerase
  • Telomere
  • Tumor-initiating cell

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Prostate tumor-initiating cells : A new target for telomerase inhibition therapy? / Marian, Calin O.; Shay, Jerry W.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1792, No. 4, 04.2009, p. 289-296.

Research output: Contribution to journalArticle

@article{874db82be8db4d45b072f73c673d171d,
title = "Prostate tumor-initiating cells: A new target for telomerase inhibition therapy?",
abstract = "Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These {"}cancer stem cells{"} are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.",
keywords = "GRN163L, Prostate, Telomerase, Telomere, Tumor-initiating cell",
author = "Marian, {Calin O.} and Shay, {Jerry W.}",
year = "2009",
month = "4",
doi = "10.1016/j.bbadis.2009.02.012",
language = "English (US)",
volume = "1792",
pages = "289--296",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Prostate tumor-initiating cells

T2 - A new target for telomerase inhibition therapy?

AU - Marian, Calin O.

AU - Shay, Jerry W.

PY - 2009/4

Y1 - 2009/4

N2 - Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.

AB - Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.

KW - GRN163L

KW - Prostate

KW - Telomerase

KW - Telomere

KW - Tumor-initiating cell

UR - http://www.scopus.com/inward/record.url?scp=64249158272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249158272&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2009.02.012

DO - 10.1016/j.bbadis.2009.02.012

M3 - Article

C2 - 19264126

AN - SCOPUS:64249158272

VL - 1792

SP - 289

EP - 296

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 4

ER -